Home Other Building Blocks 1708971-55-4
1708971-55-4,MFCD31381923
Catalog No.:AA003AON

1708971-55-4 | Fgf401

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$26.00   $18.00
- +
2mg
98%
in stock  
$43.00   $30.00
- +
5mg
98%
in stock  
$64.00   $45.00
- +
10mg
98%
in stock  
$95.00   $67.00
- +
25mg
98%
in stock  
$161.00   $113.00
- +
250mg
95%
in stock  
$1,077.00   $754.00
- +
1g
95%
in stock  
$2,950.00   $2,065.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA003AON
Chemical Name:
Fgf401
CAS Number:
1708971-55-4
Molecular Formula:
C25H30N8O4
Molecular Weight:
506.5569
MDL Number:
MFCD31381923
SMILES:
COCCNc1cc(ncc1C#N)NC(=O)N1CCCc2c1nc(C=O)c(c2)CN1CCN(CC1=O)C
Properties
Computed Properties
 
Complexity:
865  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
37  
Hydrogen Bond Acceptor Count:
9  
Hydrogen Bond Donor Count:
2  
Rotatable Bond Count:
8  
XLogP3:
0.6  

Downstream Synthesis Route

[1]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-US2015/119385,2015,A1

[2]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2015/59668,2015,A1

[3]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2016/151501,2016,A1

[4]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-WO2016/151500,2016,A1

[5]Fairhurst,RobinA.;Knoepfel,Thomas;Buschmann,Nicole;Leblanc,Catherine;Mah,Robert;Todorov,Milen;Nimsgern,Pierre;Ripoche,Sebastien;Niklaus,Michel;Warin,Nicolas;Luu,VanHuy;Madoerin,Mario;Wirth,Jasmin;Graus-Porta,Diana;Weiss,Andreas;Kiffe,Michael;Wartmann,Markus;Kinyamu-Akunda,Jacqueline;Sterker,Dario;Stamm,Christelle;Adler,Flavia;Buhles,Alexandra;Schadt,Heiko;Couttet,Philippe;Blank,Jutta;Galuba,Inga;Trappe,Jörg;Voshol,Johannes;Ostermann,Nils;Zou,Chao;Berghausen,Jörg;DelRioEspinola,Alberto;Jahnke,Wolfgang;Furet,Pascal[JournalofMedicinalChemistry,2020,vol.63,#21,p.12542-12573]

[1]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-US2015/119385,2015,A1

[2]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2015/59668,2015,A1

[3]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2016/151501,2016,A1

[4]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-WO2016/151500,2016,A1

[5]Fairhurst,RobinA.;Knoepfel,Thomas;Buschmann,Nicole;Leblanc,Catherine;Mah,Robert;Todorov,Milen;Nimsgern,Pierre;Ripoche,Sebastien;Niklaus,Michel;Warin,Nicolas;Luu,VanHuy;Madoerin,Mario;Wirth,Jasmin;Graus-Porta,Diana;Weiss,Andreas;Kiffe,Michael;Wartmann,Markus;Kinyamu-Akunda,Jacqueline;Sterker,Dario;Stamm,Christelle;Adler,Flavia;Buhles,Alexandra;Schadt,Heiko;Couttet,Philippe;Blank,Jutta;Galuba,Inga;Trappe,Jörg;Voshol,Johannes;Ostermann,Nils;Zou,Chao;Berghausen,Jörg;DelRioEspinola,Alberto;Jahnke,Wolfgang;Furet,Pascal[JournalofMedicinalChemistry,2020,vol.63,#21,p.12542-12573]

204452-90-4   
7-formyl-6-(4-methyl-2-oxo-piperazin-1-ylmethyl)-3,4-dihydro-2H-1,8naphthyridine-1-carboxylicacid5-cyano-4-(2-methoxy-ethylamino)-pyridin-2-ylamide 

[1]Patent:US2015/119385,2015,A1

[2]Patent:WO2015/59668,2015,A1

[3]Patent:WO2016/151501,2016,A1

[4]Patent:WO2016/151500,2016,A1

[1]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-US2015/119385,2015,A1

[2]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2015/59668,2015,A1

[3]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2016/151501,2016,A1

[4]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-WO2016/151500,2016,A1

[1]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-US2015/119385,2015,A1

[2]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2015/59668,2015,A1

[3]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2016/151501,2016,A1

[4]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-WO2016/151500,2016,A1

[5]Fairhurst,RobinA.;Knoepfel,Thomas;Buschmann,Nicole;Leblanc,Catherine;Mah,Robert;Todorov,Milen;Nimsgern,Pierre;Ripoche,Sebastien;Niklaus,Michel;Warin,Nicolas;Luu,VanHuy;Madoerin,Mario;Wirth,Jasmin;Graus-Porta,Diana;Weiss,Andreas;Kiffe,Michael;Wartmann,Markus;Kinyamu-Akunda,Jacqueline;Sterker,Dario;Stamm,Christelle;Adler,Flavia;Buhles,Alexandra;Schadt,Heiko;Couttet,Philippe;Blank,Jutta;Galuba,Inga;Trappe,Jörg;Voshol,Johannes;Ostermann,Nils;Zou,Chao;Berghausen,Jörg;DelRioEspinola,Alberto;Jahnke,Wolfgang;Furet,Pascal[JournalofMedicinalChemistry,2020,vol.63,#21,p.12542-12573]

Literature

Title: Nicole Buschmann, et al. Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors. WO2015059668A1.

Title: Robin A Fairhurst, et al. Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. J Med Chem. 2020 Nov 12;63(21):12542-12573.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 1708971-55-4
Tags:1708971-55-4 Molecular Formula|1708971-55-4 MDL|1708971-55-4 SMILES|1708971-55-4 Fgf401